More than 2.5 million peer-reviewed articles appear in scholarly journals in a single year – creating a deluge of data that requires a technology solution
Epilepsy, leukemia, psoriasis and dry eye are among the common and the rare diseases that saw critical FDA approvals in 2016 for new treatments. Altogether, 22 drugs cleared US government hurdles last year, less than half as many as in the year before. According to an American Chemical Society published report, 2017 should see a return to the norm of 30 approvals.
The scientists who develop these new drugs in the digital age rely on published research for the information that can open a path to discovery. Yet more than 2.5 million peer-reviewed articles appear in scholarly journals in a single year – creating a deluge of data that requires a technology solution.
UK-based Linguamatics is a world-leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support. Jane Reed heads the company’s life science strategy efforts, working with the pharma-biotech and healthcare industries to speed up the drug-discovery cycle and improve patient outcomes. As an experienced researcher in genetics and genomics, Jane knows the challenges faced from the bench side and the business side when bringing a drug through inception to commercialization.
“If you think about the whole drug discovery/drug development process – from the bench to bedside – you need insight at every single stage to answer questions,” she explains.
As the head of life science strategy at Linguamatics, Jane Reed is responsible for the life science business unit, developing the strategic vision for Linguamatics’ growing product portfolio, partner relationships and business development for pharma and biotech. Jane has extensive experience in life science informatics. She worked for more than 15 years in vendor companies supplying data products, data integration and analysis and consultancy to pharma and biotech – with roles at Instem, BioWisdom, Incyte, and Hexagen. Before moving into the life science industry, Jane worked in academia with post-docs in genetics and genomics.
On May 23-25 at the Seaport World Trade Center in Boston, Copyright Clearance Center will be among 3,300 life science, pharmaceutical, clinical, healthcare and IT professionals from more than 40 countries at the Bio-IT World Conference & Expo ’17. You’re invited to visit with CCC representatives (booth #548) to discuss your R&D team’s information challenges and how CCC’s XML for Mining and other solutions can help.